Adavale Resources Limited

ADDN

Adavale Resources Ltd. engages in mining exploration and development of uranium properties. The company is headquartered in Leederville, Western Australia. The firm is in the business of mineral exploration for nickel in Tanzania and Uranium in South Australia. The firm's projects include Kabanga Jirani Nickel Project and Lake Surprise Uranium Project. The company holds 100% of the Kabanga Jirani Nickel Project, a portfolio of over 12 granted licenses covering approximately 1,216 square kilometers along the Karagwe-Ankolean belt in Tanzania. The seven southernmost licenses are proximal to the Kabanga Nickel Deposit. The company has farmed-in to two more licenses contiguous to its four southernmost licenses, adding approximately 99 square kilometers to the portfolio (Luhuma Nickel Project). The Lake Surprise Project area is located in South Australia, approximately 550 kilometers (km) north of Adelaide, and 70 km east of Marree. The firm holds four tenements, such as EL5892, EL5893, EL 6821 and EL6598, with a total area of approximately 1,078 square kilometers.

CSR Limited

CSR

CSR Ltd. engages in the manufacture and supply of building products in Australia and New Zealand. The company is headquartered in North Ryde, New South Wales and currently employs 2,785 full-time employees. Its principal activities include the manufacture and supply of building products. Its Building Products segment includes interior systems (Gyprock plasterboard, Martini, Himmel Interior Systems and Rondo rolled formed steel products joint venture), construction systems (Hebel autoclaved aerated concrete products, AFS walling systems and Cemintel fibre cement), and masonry and insulation (Bradford insulation, Bradford energy solutions, Edmonds ventilation systems, Monier roofing, PGH Bricks and Pavers and New Zealand Brick Distributors joint venture). Its Property segment is engaged in the sale of former operating sites. In addition, this segment is involved in a small number of large-scale developments in New South Wales, Queensland, and Victoria. Its Aluminium segment relates to its interest in Gove Aluminium Finance Limited, which in turn holds an interest in the Tomago aluminum smelter.

BHP

BHP

BHP Group Ltd. engages in the exploration, development, production and processing of iron ore, metallurgical coal, and copper. The company is headquartered in Melbourne, Victoria and currently employs 39,729 full-time employees. The firm is a producer of commodities, including iron ore, copper, nickel, potash and metallurgical (steelmaking) coal. The company is focused on offering a range of resources, which provides copper for renewable energy; nickel for electric vehicles; potash for sustainable farming, and iron ore and metallurgical coal for the steel needed for global infrastructure and the energy transition. Its segments include Copper, Iron Ore, and Coal. Its Copper segment is engaged in mining of copper, silver, zinc, molybdenum, uranium, and gold. Its Iron Ore segment is engaged in mining of iron ore. Its Coal segment is engaged in mining of metallurgical coal and energy coal. The firm is also focused on operating Olympic Dam, Prominent Hill, and Carrapateena underground copper-gold mines in South Australia. Its operations are situated in Australia, Europe, China, Japan, India, South Korea, rest of Asia, North America, South America, and others.

S&P US 500

IVV

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.